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TW" -PFFECTS OF SULFANILAMID"R

Para-amino-benzene-sulfonamide (now officially
sulfanilamide) (1) still crests the wave of popularity.
Its level of therapeutic value may be ultimately found
at the crest of that wave, for the drug has withstood
severest criticism from the time of practical revelation.

Born in an ag9 in which medical science is

dominated

b~r

therapeutic nihilists, promoted in the

face of world cognizance of its attributes and sandy
foundation, and existing while these pitfalls were
illustrated and explained, no nemesis has yet been
indicated.

The only way in which sulfanilamide has

completed its undulation-- fallen from its crest-has only been apparent, for we are rising to a level
at which therapeutic value has always remained, more or
less the same, with those who have followed closely the
rules set forth long ago for safe usage.

These rules

collectively only require intelligent supervision
during administration, as will further be shown.
Probably the main factor in keeping general impression of therapeutic value from undulating was the
affair with Massengill Company of Bristol, Tennessee.
A drug known as "Elixir Sulfanilamide" was manufactured
by this concern.

The following proportion3 were used

in this "elixir" (2):
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Sulfanilemide
l\lixir flavor
Raspberry extract
Saccharin soluble
Amaranth solution 1/16
Caramel
Diethylene glycol
Water q.s.

58t pounds

1
1
1
ll
2
60
80

gallon
pint
pound
pints
tlu1dounces
gallons
gallons

This solution was tested tor flavor, according to
the Food and Drugs Act, but not tor effect on human
lite.

Consequently at least 73 persons died as a direct

result ot taking this drug.

Twenty others took the

"elixir" but the exact cause of death could not be
determined.
~orld-wide

publicity accompanied the confiscation

ot this drug during the months or September and October
in 1937.

The company sent at least a thousand tele-

grams the first day, stubborn salesmen and physicians
had to be dealt with by law, and a drag-net had to be
set from coast to coast in a heightening drama that
drew the scrutiny of all who would be interested.
Congress required a report from the Secretary or
Agriculture, and it was seen that the d1ethylene glycol
caused the fatalities.
Reverting from this parody in personal impression,
the history of sulranilamide is seen to be brief (3) (4).
In 1908 a chemist by the name of Gelino (5) was working
on the azo dyes with an industrial interest.

He first

mentioned the paraaminosulfonamide compounds.

There

was no clinical application of the azo dye stuffs until
years later when many compounds of these dyes with
sulfonamide were made.

~isenberg

their bactericidal powers.

(6) first conceived

From these investigations

sprang scarlet red, included in "New and Non-official
Remedies" by the .American Medical Association in 1912
as a valuable drug in the treatment of chronic ulcers
and wounds.

At the Dusseldorf Dermatological Society

on May 17, 1933, (2) it was reported bv Foerster that
a red dye called Prontosil had had a remarkable effect
in a child suffering from a staphylococcal pyaemia.
Subsequently there were many reports on the effects
of the dye

chi~fly

in hemolytic streptococcal infections.

Domagk (7) however, was the first to offer experimental
proof.

He pointed out the antistreptococcic action of

certain azo dyes in artificially infected animals.
Soon after this some French investigators (8) showed
that the active factor in this red dye Prontosil was
para-amino-benzene-sulfonamide, later re-named sulfanilamide.

Many other workers varified this work (9-11).

The azo dye was seen to be not the essential component.
It was proved that the p-aminobenzenesulfonamide
group is set tree by the reduction of the prontosils
in the body.

In vitro also the prontoails must be
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reduced before they become bacteriostatic.

Mietzsch

and Klarer ( 12) ( 1935) ma.de a new compound from the
original prontosil by adding an azonaphthalene ring to
the sulfonamide group.

This compound was the red dye

which has been known and used as prontosil soluble and
as prontosil and now is to be called neoprontosil.
Domagk's work with the original prontosil in mice gave
the impetus to the tremendous strides now being made in
chemotherapy.
My purpose in writing this paper is to summarize
the literature on this subject, attempting to procure,
to my own satisfaction, a working plan for use of the
drug, avoiding toxic manifestations.

A recent case of

toxic hepatitis in Omaha will be analized, and anything that may be in common with the toxic manifestations will be observed.

The use of this drug in

relation to the "practice of medicine" as well as
to the "science of medicine" will be discussed from the
influence of the reading.
It must be here stated that, since well over
two thousand articles have been published in the last
three years and several good books written on the subject {13, 14), this paper, in its brevity, can not
pretend to be unbiased in its conclusions.
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The effects of sulfanilamide and allied compounds
are well, though not completely, studied.

It is in-

teresting to know that sulfanilamide was introduced as
a specific chemotherapeutic agent for hemolytic streptococcic infections.

In such a capacity it promised

to rival salvarsan in chemotherapeutic advancements,
but it has broken from this specificity, for further
experimental and clinical trials showed that it had a
wide, but peculiarly selective, effectiveness.

Certain

organisms are influenced by it while closely related
organisms, for reasons which at present cannot be
appreciated, are entirely unaffected.
Before the time when sulfanilamide was put to
practical use clinically, there were many experiments
carried on in attempts to understand the action of these
compounds in vivo as in contrast to the action in
vitro.

Various organisms and many different experi-

mental animals have be.en used.

Many conclusions have

been put forth that warrant acknowledgement.

These

suggestions have been well summarized as follows (15):
Sulfanilamide-( 1) acts mainly as a bacteriostatic agent;
(2) stimulates phagocytosis;
(3) neutralizes bacterial toxins;
(4) is bactericidal under certain conditions;
(5) delays the growth of organisms until
mononuclear phagocytes accumulate;
(6) alters the organisms so that phagocytosis
can take place.
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The methods used have been quite variable and may
account for many of the differences of opinion.

The

action may also be different with different organisms.
The action of the drug as a bacteriostatic agent is most
emphasized in the literature (11, 16-22).

The very

history of the drug implies that it has this effect, as
has been briefly reviewed.
The point in question in study of effects here is
whether sultanilamide inhibits the growth of the
bacteria, enhances the natural body defenses so that it
can throw off the organism, or a combination of the
two.

The literature seems to show that the first of

these is most obvious, but that the Dody defenses are
bolstered as well, and now still further attributes
are seen for the drug.
great groups of effects:

There seems to really be three
(1) Those concerned with

bacteriostasis, (2) those concerned with stimulating
the natural body defenses, and (3) those concerned with
destroying the harmful effects of the micro-organism,
altering it in a way to spead the resolution of the
infective process, or destroy it directly.
In the early periods of sulfanilemide history, when
the bacteriostaticaction of sulfanilamide was many
times shown by inhibition of the growth of streptococci
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in cultures, and Colebrook, ButtlA, and O'Meara (20)
even exerted a belief thet there was a bactericidal
effect in the presence of whole blood, it was immediately though: that a similar effect in vivo might be
the source of the therapeutic activity of the compounds.
However, those workers who did find evidence of an
inhibitory effect (23) felt that it was too slight
to account for the remarkable qualities of the drug.
Many d1.fferences in technique vary the results.
Long and Bliss (13) state, "We were unable to test,
satisfactorily, strains of hemolytic streptococci belonging to Group F, owing to the fact that with these
minute organisms large inocula are required to start
growth even in drug-free broth.

vfuen su.fficiently

large inocula were used no bacterioatasis was found.
The same was true for the minute members of Group G,
although the regular streptococci in this group were
highly sensitive to sulfanilam.ide."
the inoculum is very important.

Thus the size of

In the same way these

men have shown that the age of the culture, the virulence
of the culture, difference in the medium, dilution

or

the medium, s.nd other factors, make 1 t impossible to
draw any definite conclusions, but the fact that some
ben1f1 cie.l findings ere almost omni pre sent is an unimpeachable fact.
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Mellon, Gross, and Cooper (14) bring up the
question of possibility of a shock effect of sulfanilamide.

They bring up the point that there is always a

possibility that the infection of a foreign substance
intravenously may in certein patients bring about a
reaction.

No more material is apparent in this point

since their writing.
In connection with the idea thst sulfonamide
compounds aid 1n phagocytosis Levaditi and Vaisman (23)
advanced the theory that these compounds in some way
interfere with the development of the capsules of growing streptococci and thus deprive them of their virulence.

This would be of special interest in study of

action on pneumococci.

The many works of these authors

(23) do not lead to any definite conclusions regarding
relation to phagocytosis, and they are one of the most
dominant teams working on the question.

In May, 1935

these men state that phagocytosis was only vigorous
in the control mice of their experiments; Levaditi
later claimed that an "1ntraleukocyt1c culture" was
responsible for this confusion and stated that phagocytoais was enhanced; in June, 1935 they decided that
it was more probable that the defenses of the germ

were lessened; two years later their conclusions were
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still not definite.

Other writers seem to offer the

same indefinite results.
It is of note that the leukocyte pattern of the
blood is not changed in any way by administration of
sulfan1lam1de or allied compounds (24, 25).

The blo0d

elements found in the tissues are also unchanged (26).
Moreover, the sulfonamide derivatives have been found
by a number of observers to be harmless to various
kinds of tissue cells in cultures when applied in the
concentrations used therapeutically (23, 29).

Further,

it has been shown the,t no chemotropic effect upon
polymorphonuclear leukocytes is exerted (28).
The effect of sulfonamide compounds on the toxins
of various micro-organisms or on the toxic affects of
these infectious elements is a pressing question.

This

carries still deaper into detailed pathologic study.
The effects of the compounds on various toxins have
been studied by many men.

Osgood and Brownlee (29)

claim thet sulfanilamide neutralized the hemotoxin of
streptococci after the manner of an antitoxin.
By

complicated study of the metabolism of micro-

organisms which have been subjected to therapeutic
concentre.tion of sulfonamide compounds, it has been
suggested by many works that, since this metabolism
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is in many instances altered, there may be a direct
bactericidal affect in some conditions (30-33).
The most recent work to be published is that of
Lockwood and Lynch (34).
will incite a

differ~nt

If this work is varified it
ettitude toward the mechanism

of action of sulfanilamide than is now generally
believed.

These workers observed that amounts of

peptone of only 1

mg~

in culture medium had a definite

effect on the population curve, with or without sulfanile.mide, emphasizing the practical inaccuracy of
most of the experimental work on the bactericidal
action of blood and serum.

Certain bacterial strains

(apparently most of them) require these products of
protein cetabolism to obtain nitrogen for their own
metabolism.

Thev seem unable to utilize the more

complicated combinations.

Thus, normal hurne.n serum,

without sulfanilamide, 1 s not a good medi ·iJm for propagation of even relatively invasive strains of hemolytic
streptococci.

On the other hand, the addition of

peptone made the serum favorable for even the less
virulent strains.

The effect of sulfanilamide in vitro

is, therefore, only maximal when even small traces of
peptone are eecluded from the serum.

Hence, it is

likely that under these circumstances the serum medium
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is deficient in the readily assimilable nitrogen
necessary for biologic activity.
Lockwood and Lynch worked on the hypothesis that
sulfanilamide interfered with the ability of hemolytic
streptococci to utilize protein-split products in serum
and that the presence of peptone provided assimilable
nitrogen in such excess that sulfanilamide could no
longer act with optimal effectiveness.

They state,

"The precise mechanism by which peptone interferes
with the action of sulfanilamide is, we believe, necessary for any fundamental understanding of the action of
sul.fanilamide in vivo."
Working with freshly drawn human blood serum,
defibrinated with glass beads, and an inoculum of young
hemolytic streptococci, they prepared a series of tubes
to incubate.

In these were various concentrations of

peptone and aulfanilamide together and separate.

The

same procedure was used with Bacillus coli in urine,
and in a similar way the action of sulfanilamide on
pneumococci and staphylococci, in human seriun, was
studied.
The population curves of the various concentrations show that by decreasing the concentration of
sulfanilamide or increasing the concentration of pep-
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tone the proliferation of the micro-organisms is enhanced by some direct or indirect fashion.

The addi-

tion of peptone to sulfanilamide-free control serums
produced a marked increase in the rapidity of outgrowth.
A concentration of a hundred times as much sulfanllamide
as peptone is necessary to produce bacteriostasis
that is as great as in peptone-free serum containing
sulfanilamide.
In the same work, Lockwood and Lynch experimented
with urine and soon saw that in the presence of peptone
sulfanilamide no longer had the power to reduce the
population curve of the colon bacillus.

They point

out the fact that in the course of tissue breakdown
peptone is present in plentiful amounts, s.nd that this
could account for the favorable action of sulfanilemide
in the more generalized inf'ections as contrasted to its
failure to get response in more localized morbidity,
in most instances and reports.

Ballenger and his

associates (35) show that conditions in the urinary
tract which might lead to an increased production of
products of tissue breakdown may account tor failures
of sulfanilamide therapy.

Coincidently this seems

highly feasible.
The same relations between concentration of peptone and sulfan1lam1de are shown with Staphylococcus
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aureus are shown, and the effects of peptone on the
actions of sulfanilamide and sulfapyridine on streptococci and the pneumococcus type III are studied.

In

the latter the action of sulfapyridine seems superior.
It is of special note that the presence of from
0.01 to o.l mg of peptone to a large extent overcomes
the bacteriostatic effect of even 1 mg per cubic
centimeter of sulfanilamide (See later-- local implantation).
With reference to the possibility that sulfanilamide may act as an anti-catalase, these writers point
out that it acts on Bacillus coli which is generally
considered to be highly resistant to the lethal effects
of hydrogen peroxide.
Lockwood and Lynch offer amazing comment:

0

Normal

human serum does contain minute auantities of free
amino acids and other derivatives of protein catabolism.
Since the organisms that are known to be susceptible
to sulfanilamide are not in general actively proteolytic, it is reasonable to suppose that when they are
inoculated into blood serum they depend at least in
part on obtaining assimilable nitrogen for protein
metabolism from previously hydrolyzed protein.

Since

the concentration of such free amino nitrogen is rarely
high it is obvious that the addition of very small
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traces of peptone may markedly alter the amount of
assimilable nitrogen and thus significantly improve
the status of the serum as a culture medium for nonproteolytic organisms, such as the hemolytic streptococcus.

The fact that effective sulfanilamide action

depends on the exclusion of added peptone suggests
immediately that the drug must act in some way through
interference with the ability of the-bacteria to utilize
the traces of assimilable nitrogen in whole blood,
serum, urine or other body fluids.
"It is possible that sulfanilamide combines in
some way with the free amino nitrogen of protein
degradation products and renders them unsuitable for
bacterial utilization.

This particular point is still

under investigation, but other possible explanations
of the precise mechanism involved are also being studied.
Such a concept would appear to explain why the sulfanilamide compounds are active only age.inst certain organisms and in certain specialized mediums.
"Furthermore, it would explain the failure of
sulfanile.mide to destroy hemolytic streptococci in
localized areas of tissue proteolysis, such as abscesses or hAav1ly traumatized wounds.

It would account

for the failure of these drugs to act on the localized
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suppurative lesions of staphylococcic origin and the
successful results which have at times attended its
use in diffuse staphylococcic cellulitis and bacteremie..
This hypothesis is consistent with the spectacular
effects of sulfapyridine in pneumococcic infections,
because of the minimel tissue injury in the lung in
pneumococcic pneumonia."
There will probably be much work similar to this,
and its relations to the now prevailing concepts of the
action of the sulfonamide compounds

se~m

obvious.

This

summary of the article will be later referred to.
As previously shown,

sulf~nilamide

was first

thought of as a specific for hemolytic streptococcic
infections.

This concept has waned.

The following

outline (36) summarizes well the morbid conditions
upon which the drug has a satisfactory, therapeutic
effect.

This is here presented as a foundation for

discussion "t;ecause it seems most representative of the
literature.
CASSS IN imICH SULFANILAMIDE IS CERTAINLY US'SFUL

Acute hemolytic Streptococcus Infections.
Streptococcus Meningitis.
Primary Streptococcus Peritonitis.
crrysipelas.
Streptococcus Septicemia from any source.
Puerperal Infections.
Colon Bacillus Infections-- particularly of the Urinary
Tract.
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Men1ngococcus Meningitis and Meningococcemia.
Gonococcus Infections.
Undulant Fever (Brucellosis).
Chancroid (Ducrey•s Bacillus).
CASES IN WHICH CLINICAL RESULTS ARE L~SS CERTAIN BUT
IN WHICH THt<: DRUG MAY B"' OF VALUE
Acute Streptococcus Infections.
Tonsillitis
Bronchopneumonia
Otitis
~mp ye ma
Mastoiditis
Cellulitis
Sinusitis
Adenitis
scarlet Fever
Cholecystitis
Pneumococcus Infections.
Urinary Infections with B. Proteus, R. Typhosus,
Staphvlococcus e.ureus, and possibly other organisms.
Gas Bacillus Gangrene.
Ludwig's Angina.
Nonspecific Colitis.
Malaria.
Trachoma.
CASES IN WHICH

SULFANILAMID~

IS OF DOUBTFUL OR NO

VALUE
Most forms of Infectious Arthritis (lately successful).
RheWD8.tic Fever.
Staphylococcus General Infections (lately successful).
Influenza Bacillus Meningitis.
Friedlander Baclllus Infections.
Putrid Lung Abscess.
Urinary Infections With Streptococcus Fecalis.
Subs.cute Bacterial ~ndocarditis.
The earliest experiments, as shown in the introduction, were with peritonitis in eeperimental animals.
It is essential that chemotherapy be started early,
before the peritoneum is much damaged.

Meningococcus

and gonocoecusinfections are remarkably held for resolution by sulfanilamide.
In cases of streptococcie meningitis the use of

1'7

sulfanilamide has been found to bring amazing results.
The disease was formerly thought to be practically
always fatal.

It was only a chance of one in a hun<lred

that recovery would be reached.

Gray (37) found only

65 cases with recovery in the medical literature, and
most hospitals have few records of recovery prior to
use of sulfanilamide.

In Johns Hopkins hospital (38)

all patients admitted with this disease died, prior to
institution of chemotherapy with sulfan1lem1de.
Schwentker, et al (38), first reported the complete
recovery of a patient suffering from such an infection
in which the recovery was without a doubt due to administration of the drug.

This marked the beginning of a

new series of vital statistics as far as the disease
was concerned.

Arnold (39}, and Smith and Coon (40)

also reported recoveries in the

sam«~

year, and since that

time there have been numerous reports of the successful use of aulfanilamide in the treatment of
streptococcal meningitis (41-43).

h~molytic

Neal (44) used a

combination of neoprontosil and sulfanilamide.

Long

and Bliss (13} point out, however, that there is quite
definite proof that Neoprontosil does not pass over
into the spinal fluid, so there is little evidence which
warrants the belief that the combined use of the drugs
in hemolytic streptococcal meningitis is more effective
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than is that of sulfanilamide alone.

They state

(page 169 in #13), "The available evidence tends to
show that sulfanilamide has reduced the case fatality
rate in hemolytic streptococcal meningitis from 97 per
cent to about 35 per cent.

This latter figure oan be

made lower if the disease is recognized in its inception and then intensively treated with sulfe.nilam1de."
It is surprising that the literature offers so
few references to streptococcus peritonitis.
associated with puerperal infections.

Most are

Colebrook and

Kenny (24) reported a series of cases of puerperal
sepsis treated with prontos11.

or

the ten patients,

there were four with generalized peritonitis and six
in which there were indications of a beginning generalized peritonitis.
one fatality.

In this group of ten, there was

Foulis and Barr (45) reported four cases

of generalized peritonitis with three recoveries.

Long

and Bliss (11) report one case with complete recovery.
A recent article gives some good results with use of
sulfanilamide in treatment of per1ton1t1s associated
with appendicitis.

It is to be noted, however, that

this series is not of specific infection, (46).

With

reference to their series of peritonitis cases in
general, they state, "The mortality in e. series of
809 consecutive cases of acute appendicitis has been
reduced from 1.5% in the first 552 cases to 0.4% in
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the last 257 cases.

This improvement is, we believe,

the result of the employment of sulfanilamide in all
severe cases in the latter group."

In relation to

feasability they state, "Sulfanile.mide readily diffuses
into the peri ton,~al fluid in the experimental animal.
All the available material indicates that the poritoneum is a favorabl3 site for the action of sulfenilamide."
....

If means could be used to diagnose cases of primary
streptococcus peritonitis, it is most probaule that the
mortality and course of inf'ection could be reduced
amazingly by employment of sulfanilam1de.
There can t)e little doubt that the introduction
of the sulfonamide compounds in chemotherapy has considerably reduced the mortality of erysipelas.
Toomey (47) reported 1907 cases.

In the 1313 untreated

cases the mortality was 15.5%, in those in which
antitoxin was used (520) it was 13%, and in 74 cases
in which sulfanile.mide was used the mortality was

4%.

Snodgrass and his associates {48, 49) have shown that
the mortality from th3 disease in the Ruchill Hospital
in Glasgow, Scotland, has been reduced from 7.93 to
2.3~.

These workers all show that the clinical course

of the disease is shortened as well es its danger to
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life lessened.

The disease has always claimed more

pAople in the aged and young groups.
to be especially aided by the drug.

These groups seem
If any abscess

formation occurs, surgical drainage should be instituted
to hasten recovery.

Dosage for the infection is quite

as is used in other cases, however, some feel that it
is especially important to have a high blood-concentration of the drug here.
Most of the cases of septicemia, as with the
peritonitis cases, are in relation to puerperal infection or local infection or such, where the diagnosis
is inferred.

Colebrook and his associates (20, 24)

in 1936 reported 12 cases of hemolytic streptococcal
bacteremia among their puerperal sepsis cases.

Of

these, eight were uncomplicated by coexisting peritonitis.

These patients were treated with prontos11.

5,oon
colonies on the first two days of treatment, 3,ooo
In one of these cases the blood culture showed

colonies on the third day, and on the fourth day of
treatment the blood culture was sterile.
was discharged on the twenty-first day.

The patient
In another

case, aultanilamide therapy tor four days resulted
in normal temperature and pulse, and in sterility of
the blood which had previously yielded positive cultures.
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In a third case the blood culture became sterile on
the third day of treatment, metastatic abscesses associated with the bacteremia rapidly resolved, and the
patient's general condition raridly improved.

In a

rourth case, there was a spectacular remission of the
signs and symptoms in twenty-rour hours after the
beginning of treatment, followed by a steady improvement of the patient's condition.

There were three

fatalities in this group of 12 patients.

Foulis and

Barr (45) encountered only one fatality in their series
or cast:ts of puerperal sepsis among which eight, including the fatality were septicemic.

Robinson (50)

presented a case of hemolytic bacteremia with bronchopneumonia following tons1llar enlergement and purulent
cellulitis in the neck.

Incision and drainage in the

neck region was instituted and ant1soarlat1nal serum
and sulfanllamide were used and the patient recovered.
Seal (51) presented a case which followed a sinusitis
and had concomittent joint involvement and recovered
after administration of the drug.

McCarthy {52) re-

ported a case of postscarlatinal hemolytic streptococcal
septicemia which was cured e.fter use of neoprontos11 e.nd
sulfan1lam1de.

~-.111tby

favorable results.

(53) reports tour out ot five

In all these reports it seems to
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be essential that chemotherapy be maintained until
complete recovery is obtained.
Other forms of septicemia. have been reported as
responding fevorably to administration of the drug.
Dyke ( 54) has reported that the ad.mini stre.tion of
sulfapyridine brought about a prompt recovery in a
patient who was 111 with a pneumococcal septicemia
occurring a.fter a lobar pneumonia which
psnied

b~1

empyema..

wt::.

s accom-

O 'Bri~n e.nd McCarthy ( 55) noted

the recover;r of a patient who had been ill for sixteen
days with a staphylococcal septicemia.

Quite recently

(56) two cases of bacteremia with Staphylococcus

aureus hemolyticus were treeted

b~.~

administration of

sulfanila.mide with good results.
Colebrook and his associates in 1936 (24) showed
that there were such remarkable results from the use
of the sulfonamide compounds in puerperal sepsis that
the fatality of the infection could be astonishingly
reduced.

Their work is so clear that it leaves no

room for doubt.

The clinical reports of publications

since ths.t time h8Ve not been able to enlsrge
point to any considerable extent.

UJ-'On

th'3

Further reports

seem only to substantiate the more early work.

Colebrook

et al (5ry, 58), used the Prontosils in their treatment
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and these drugs are still used in this disease.

It

was this early work which led to the more or less
general use of the prontosils in cases where the infectlng egent is a hemolytic streptococcus.

There

doesn't seem to be much indication the.t thev e.re effective in puerperal sepsis due to the anaerobic group
of streptococci.

Colebrook and Kenny (57) reported

that from 1931 through 1935 the rnorte.li ty in p11erpere.l
infections in Queen Cherlotte•s Hospital that werfl due
to hemolytic streptococci varied from 16.6 to 31.ri
per cent per year, while the number of deaths from
streptococcal peritonitis varied from 15 to 23 per year
during the same period.

Prontosil therapy was started

in January, 1936, and from then until August, 1936,
64 patients 111 with hemolytic streptococcal puerperal
sepsis were treated, with a case fatality rate of
4.? per cent and one death from peritonitis.

It was

further noted in the treated patients that no pelvic
masses developed arter treatment had been commenced.
A prompt fall in the temperature within twenty-four
to seventy-two hours was noted in the majority of the
patients treated with the Prontosils.

Rarely were

recurrences of the fever encountered.

Twelve of the

64 pvtients had blood cultllres positive for beta
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hemolytic streptococci when there_py was bEL1,un,
and of these, nine made a prompt recovery.

It was

brought to Colebrook's attention that the case futality
rate of the patients 111 with streptococcal puerperal
f19ver ad.mi tted to the Northwestern Fever Hospi te_l in
London had declined from 22 per cent in 1933 to 5.26
per cent for the first half of 1936, while no such
decline had been noted in the fatality rates recorded
in puerperal sepsis in nueen Charlotte's Hospitel during the same period.

Thus there was the ouestion of a

decline in virulence of the hemolytic streptococcus
rather than the effects of Prontosil therapy which was
causing the changed fatality rate.

However, it was

observed that, whereas the rates dropped at Northwestern Fever Hospital, 'tt was only after the institution of Prontosil therapy that the death rate dropped
at Q:ueen Charlotte's Hospital.

Also it was concl1Jded

that twenty or thirty of the more severe cases surely
must have responned to th::i drug, for the recovery was
phenomene.l.
Coming to the urinary tract in the originally
accepted outline for this therapeutic discussion it
has this month, since the work of Lockwood and Lynch (34),
become advisable to dissertate:

Mellon and fellow
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workers ( 32, 59) presented the ''Phenomenon of Potentiation".
out

lF~ngthy

In explaining this phenomenon they cerrted
experiments.

'l1hese men had a cc..se of

meningitis which recovered with grBet rapidity after
the administration of sulfanilamide.

They used the

bacteria from this cese for in vitro experiments since
they assumed sulfanilamide should undoubtedly have
remarkable effect on this strain.

They made their

dilutions using a broth as a diluting D"enstru··im, and
found that the bacteriostatic effect of the aulfanilamide was completely lost in 24 hours, and wa.s not s.s
appreciable, as it surely was in their patient.

They

then pro ceded to use various dil1;tions of serum and
combinations of serum end broth, and found the bacteriostatic action of the sulfanilamide still not sufi'icient to account for thA remarkable effect in vivo.
Next they made their dilutions in an 0.85 per cent
solution of sodium. chloride and founn that

th~

number

of colonies was less with and without the sulfanils.mide.
They here pointed out that this solution of sodium
chloride itself had a bacter1ostat1c effect.

The

bacterioststic efi'ect was then studied when serum and
salt were used in verious dilutions, and then they
carried out the dilutions with ser1Jm, salt and sul-

26

fanilamide.

Here they found that instead of a summat-

ing bacterioste.tic effect of the salt and the sulfe.nilamide an even far greater static effect was noted.
Therefore, they concluded thnt there was a "potentiating" effect of the salt so that the effect of the sulfanilamide approe.ehed thB.t cssumed to have taken rlace
in the body of the pstient with the remarkable recovary.
Besides showing the probability of many mistakes
being made in such wor•k, they also brought up me.ny
new questions relative to the effects of aulfanilamide.
Many of these were directed to therapy in urinary tract
inf'ections.

"Does the urine potentiate sulfanilamide's

action in infections of the genito-urinary tract?"
they ask.

They poin'::.. out that in cases of cystitis,

pyelitis, and such it seems most possible that the in
vitro bacteriostatic effect of the sodium chloride
could be transferred.
Kenny, et al (60) have shown remarkably rapid
sterilization of the urine in 4o cases of pyelitis due
to Bacillus coli after administration of' sulfan1lem1de.
The urine often contained as many es 125 m11L1.on
organisms per cubic centimeter in advance of

tre~tment.

In attempting to find the ans ver to their quer,:'y
1
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concerning urinary tract infections Mellon, et al
prepared a series of dilutions, seeded with a microorganism obtained from a cystitis ce.se.

Th'3 dilutions

were mcde, respectively, in broth alone, urine and
broth and urine alone,

80

that all possibilities of

combinations of' culture medium, diluent, test medium
and concentrations of sulfanilamide were used.

From

this work they had wonderful evidence to conclude that
"a critical be.cterioste.tic ef'fect of sulfan1lamide can
only be obtained in vitro under conditions where the
organisms are not only tested in urine, but diluted in
urine e.s well.

If they are diluted in broth, even though

the tests are made 1n urine, the effect of the sulf'an1lamide is negligible."
Thus it was shown that thP. sulfanilamide worked so
marvelously in urine because urine was the only medium
present.

The urine, they theorized, had the "poten-

tiating effect" that they had previously attributed
to a solution of normal saline.

They also pointed out

that when there was any tissue destruction present in
cases of pyelitis or cystitis the sulfanilBmide no
longer was

a8

effective.

This, they argued, was due to

the changes in the chemical make-up of the urine in
the presence of the protein cstabolism, end was quite
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similar to their in vitro experiments where they
diluted their seeded urine with broth or used the
broth as a test medium.
Now this work must be correlated with the recent
work of Lockwood and Lynch (34), previously described.
It will be remP-mbered that they concluded thet sulfan11am1de acted only in the presence of a limited amount
of peptone, and thus they explained the fact that the
drug could combat an acute, generalized infection,
whereas, it could not cope with a situation in which
there was tissue destruction, because of the presence
of an overwhelming amount of peptone from protein
catabolism.
In projecting Lockwood and Lynch's work on that of
Mellon, et al,

~e

can see that the reason sulfanilamide

acts in the urine dilutions and not in the broth dilutions, in the saline dilutions and not in the broth
or broth-serum dilutions, is that there is plenty
available nitrogen in the form of break-down products
of protein in the broth, which are obviously not present in the sBlt, or appreciably so in the urine.
However, es pointed out, the drug did not work in the
face of tissue destruction.

Here again it could be

that this is because of the presence of peptones.
This seems a logical explaination of a great work.
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The urinary tract infections, as above described,
are much nee.rer in vitro experiments than anything
worked with heretofor.

Once more 1t seems that the

urologists have the oportunity to do thourough work,
with a profound understanding, beceuse they can see
whHt they are doing.

On the other hand, if this work

holds up, the action of sulfanilam1de throughout the
body can now be better visualized.
1.\Torking in this body system, and with these
theories, another major point is brought to view.

That

point is the complete lack of specificity of the
sulfonamide compounds.

It is now more than ever seen

that it is not the genus or species of the microorganism that is concerned so much as the manner in
which it manifests itself in its morbid activity in
the body.

Many micro-organisms seem to have no sus-

cepta.bili ty to the therspeutic action of sulfanilEimide
whatsoever, but the most of them have shown some weekness.

In the body, however, many of these infectious

agents manifest themselves in such a manner that it is
improbable that they will ever be satisfactorily combated bv these known methods of chemotherapy.
In a recent article (36) some cases of urinary
tract infections were analyzed according to the or-
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ga.nisms in the following cha.rt:
URINARY rpRACT INF';'CTIONS ACCOHDING TO ORGANISMS

Cases
B. Coli
B. Proteus
B. Friedlander
B. Pyocyaneus
Staphylococcus aureus
Nonhemolytic Streptococcus
H:nterococcus combined with B. Coli
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Cured
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12
2

2
0
1
1

2
2
2
3

2
1

N""
A great many different micro-organisms have been
e'~perimented

w1.th and tried in clinical combat.

It

is sufficient to say here that most have some response
reported, so the drug may be tried, at least.
It is important to beware of kidney damage in
administration of sulfanilam.ide.

After several days of

chemotherapy there will be a considerable hBaping up
of blood concentration of sulfanilamide if it is not
properly excreted.

Another important thing to remt=imber

in dealing with the urinary tract is that a.bout half
or the drug is in the urine in its inactive conjugate
form.

This is the acetyl derivative that is also

found in the blood stream.

There is a considerably

greater amount of this form found with the administration of sulfa.pyridine, but this drug is superior in
action in many instances.

Because of the greater

amount or the conjugate form, crystals often bring
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havoc es will ltiter be shown in the discussion of 111
e.ffects.
Schwentker, Gelman, s.nd Long (61) withheld specific
mAningococcal antiserum in ten cases of meningococeal
men1ngi tis 1n 193'7.

Instead, they administered sul-

fanilamide subcutaneously and 1ntrasp1nally, and all
but one o.f these patients recovered.

The one .fatelity

was very ill on adnission and was considered lost anyway.

There were signs o.f encephalitic involvement in

this case, and concomittent pneumonia was met on the
.fi.fth day.

The spinal fluid of this patient had been

sterile for three days and there was a mBrked reduction
in the spinal fluid cell count to 158 cells on the day
of death as a result of sul.fanilamide therapy.

All

petients responded with a reduction in the spinal
fluid cell count which occurred progressively beginning
with the institution of the therapy in some eases and
precipitously, e.fter several days, in others.

The

spinal fhlid and the blood during this time !Jece.me
sterile.

In addition, a child that had meningococcal

sept! cemis. without meningitis, ''as also cured in thA
same mannar.
Harvey and Janeway (62} mentioned the case of e.
ten-month-old baby manifesting meningococcal meningitis
that was recovering as a result of sulfanilernide therepy,
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but developed hAmolytic anemia which necessitated a
number of blood transfusions.

The petient recovered.

Among the more extensive confirmatory papers ere those
of Banks ( 63) and ,,,e.ghe lste in ( 64 ) •

rrh~

se and many

more reports show this to be one of the astounding uses
of the sulfonamide compounds.

There are me.ny points

to consider in therapy here, the details of which
cannot be

dis~1ssed.

There ere differences in which

the sulfonamide compounds diffuse into the spinal
fluid.

The f·rontosils seem to diffuse most poorly.

There is a lag in the concentration in the spinal fluid
as contrasted to the blood concentration.

The use of

intraspinal administration has been less prominent
in late reports, but it may have its place.
tions with antiserum

~re

Combina-

used also.

Long and Bliss (13, page 188) report excellent
curative results after intensive there.py with the drug
in five patients suffering from acute meningococcemia,
without signs of meningitis.
One of the most important developments in the
administration of sulfanile.mide was the introduction of
treatment of gonorrhea by this method.
significant reports with

favorabl~

The first

results were by

De9s and Colston {65) and Herrold(66).

Since that

time a great deal of literature is to be found.

Among
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the few who found unsatisfactory response are AnwylDavles (67), and Brunet, Reinhardt

an~1

Shaw (68).

There is no unanimity of opinion ns yet, regarding the
optimum time for beginning treatment, the amounts of
th~

drug that should be used, the duration of therapy,

or the auxiliary measures which should oe instituted
in the course of treatment.

It seems, from a review

of the various opinions upon the subjBct, that the
later therapy is started in the course of the disease
the more successful are the ultimate results.

In

Dees and Colston's original paper (65), it was noted
that while failures in treatment occurred in only 7.5 per
cent of fresh cases, 11.5 per cent of the patients
previously treated by other methods did not respond to
sulfani lamide.

Herrold, however, reported the.t only

four of 14 patients 111 with acute gonorrhea made a
quick response to sulfanilamide therapy.

He also

advanced the possibility that better results would be
obtained in new infections if the petlent had previously
had gonorrhea than in those individuals suffering from
their first attack.
Many of the early reports on the use of the sulfonamide compounds were dissappointing because the
wrong drug was used.

Prontosil therapy is now known
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to be unsatisfactory.

.4.s

before brought out in this

paper, in view of the present knowlHdge of drug action,
the effects in the urinary tract ar9 quite similar to
the in vitro reactions, and the prontosils must be
reduced to an active form in vivo before they will
have a bacteriostatic effect.
agent in the

urin~

There is no reducing

of sufficient power to do the work

of the magnesium powder in vitro.
ll\fi th reference to the previously made ste tement
that it seems that therapy is best started after the
disease has been active for a few days or more, Alyea
and his co-workers (69) concluded from their studies
that the patient who starts treatment a week after the
onset of his discharge has an equal chance of being
cured with one who :Jegins treatment

~arlier.

Breakey

and Harrold (?O) however, reported that the average
duration of infection was twenty-one days in their
acutely 111 patients, and fory-five in the chronic cases
when treated with sulfanilemide.

This is to be con-

trasted with an average duration of infection of one
hundred and four days in 50 of their patients treated
previous to the introduction of sulfanilamide.

Colston

and his associates (71) divided their patients into
those who had anterior urethritis, anterior and post-
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erior urethritis, and anterior and posterior urethritis
with complications.

The average duration of the disease

in these three groups was twenty-seven, twenty-eight,
and thirty-three days respectively.
In the last year there have been reports, too
voluminous to describe in this paper, of the use of
other sulfonamide compounds in the treatment of gonorrhea.

Many men are now using sulfapyridine for chem-

otherapy here.

Since this drug acts in a fashion

similar to sulfanilamide, and in many instances show
greater action, it is probable that the success claimed
for it is well founded.

It must be

rf:~membered

that

well over half of this drug is in the acetyl derivative.
This product is inactive and is to produca harmful
crystal deposits in the urinary tract.

Consequently,

the drug must be used '·'i th care, and the fluid balance
of the patient es well as his acid base balance must
be well watched.

Theso, dangers will be discussed later.

Roth (72) reported a series of cases of specific
urethritis, for which he used Disulon, a brand
sulfan1lyl-sulfanilam1de, for chemotherapy.

~f

In a

group of 44 cases of acute gonorrhea treated with
sulfan1lam.1de he obtained a 47% fraction of complete
cures in two weeks.

In a series of 22 cases that were
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treated with sulfanilyl-sulfanilamide he o'otained
73% cures in this same length of tiMe.

In a series

of his private cases, at the same time, he reported
?1% of 42 cases resulted in two-week cures when treated
with potassium permanganate irrigations and sulfan11amide.

1:V1th the same irrigations but .'ITith Disulon as a
1

chemotherapeutic agent he obtained 92% cures in two
weeks.

There were also 12 cases which did not respond

to sulfanilamide that did respond to Disulon.
In the face of such reports as this for other
derivatives, it surely is advisable to try sulfapyridine
or sulfanil:yl-sulfanilamide if good results cannot be
outained with sulfanilamide.
That sulfanilamide is extremely beneficial therapeutically in oases of uncomplicated gonorrhea has
been shown by many workers (65,66,73-76) however,
there are still other attributes offered for the drug
in infections where the gonococcus is the infectious
agent.

Coggeshall (7?} et al report a series of cases

of arthritis from the gonococcus.

They showed that in
'

cases of gonorrheal arthritis the sedimentation rates
fell very rapidly upon administration of the drug,
showing striking and immediate relief.

The sedimen-

tation rates remained the same for a similar series or

3'7

cases suffering from rheumatoid arthritis where no
change of the clinical course was observed.

They

showed how the largest percentage o:f clinical cur>es
can be obtained in pe.tients 'd th gonorrh9al arthritis if
sulfanilamide in doses sufficient to maintain a bloodaulfanilamide level of 10 mguf' or higher is maintained
for a week or longer, and it is administered early.
There is a recent report (46) of a series of 100
patients with gonorrhea who were treated with sulfanilamide alone resulting in 45% cures in two weeks.

The

writers suggested that giving vitamin C with the drug
would improve the figures.

They also used it with

gonococcic vaccine and obtained 81%' two-week cures.
'*'ithout a doubt, the use of aul:fan11amide in treatment of gonorrhea will do a great deal in helping to
rid the populace of disease, and to relieve them in
suffering.
Brucella infections have attracted much interest
of workers with sulfanilamide.

There is a good deal

of work done "1th these micro-organisms to try and
determine whether or not the drug has any effect on
antibody formation.

Welch, Wentworth and Vaisman (78)

did much work on this subject and finally concluded,
"In Brucelle. infections sul:fe.nilam.ide appears to act
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through stimulation of the defense mechanism of infected
animals by increasing the production of specific
opsonins, thus effecting neutralization of the endotoxin or aggressin-like substances, with resulting
phagocytosis.

11

Kato and Lane (ry9) reported the case of a sixyear•old girl suffering from undulant fever who was
treated with sulfan1lamide.

Two relapses occurred,

each of which was also similarly treated.

No conclusions

were drawn nor was any statement made of the effect
of the drug on the clinical course of the disease.
Heretofore, chancroid has been a stubborn affliction to handle.

Therefore, the medical field is pleased

with the marvelous results obtained with sulfanilamide
therapy.

Many workers have reported good response

(80-84).

Hutchison (81) has observed that formerly it
required an average hospital attendance of forty-six
days before a che.ncroid with or without bubo was
cured, and incision of the bubo had to be performed
in five out of six cases.

Since the introduction of

sulfanilemide therapy in this disease he had not
performed an incision and the average hospital attendance had been reduced to fifteen days.
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A great deal of the illness found among patients
in a general practice is due to tonsillitis, pharyngitis, and sinusitis.

Since the introduction of

sulfanilamide it has carried the reputation of being a
more or less specific drug for streptococci.

Con-

sequently in many cases of pharyngitis it has been
immediately administered because of the impression
that most of such infections are due to the streptococcus.

Even when this is the infectious agent, it

must again be

emph~sized

that the material on the

effects of the drug, more arrl more show that it is not
the infecting micro-organism that is entirely responsible for whether response will be had or not.

The

way in which that infecting agent manifests itself in
the morbid condition must also be considered.
In agreement with many men recently before them,
Rhoads and Afremow (85) report e series of sore throats
from which hemolytic streptococci were cultured.

Half

were treated with sulfanilamide and half were not.
Some cases had to be dropped from the series because of
toxic reactions whicll necessitated the discontinuance
of the drug after a few days usage.

They found the

drug not to reduce the severity of the symptoms,
shorten the period or incapacity or reduce the incidence
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of complications.

The carrier state was also sePn not

to be shortened because the cultures were positive for
a longer time in the treated group.

The treeted group,

probably coincidentally, wes hospitalized longer than
the control group.

Careful study of the reports

presents the impression that if
not labeled on? could

no~

th·~

two columns were

tell one from the other.

The

only differences in the courses of the two columns is
that toxic manifestations of the drug other then the
usual cyanosis occurred in one half of the cases in
which sulfanilamide was administered.

In some instan-

ce a these reactions even brought serious concern.
These writers conclude,

11

It is not wise to make sweep-

ing generalize tions on the base of one serie a of
controlled ca.sea.

Sulfanila.roide is a drug of proved

value in severe infections of deep structures due to
the hemolytic streptococcus.

Rowever, in the average

uncomplicated case of tons:tllitis orpharyngitis due to
hemolytic streptococci the advisability of its routine
use is questionable.

Certainly no physician shnuld

be censured for withholding the drug in these conditions unless complications such as severe cervical
adenitis, para.nasal sinusitis, ot1-tis media., mastoiditis or meningitis supervene. 11
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Long e.nd Bliss noted that sulfanilan;ide therapy
radically altered the course of
otitis media (30).

a~1te

streptococcal

Since that time many other ob-

servers (86,42} have varified their reports.

Hageman

and BlakA (86) reported that all of 11 patients suffering from otitis media recovered from their d:isease,
without complications, following sulfanilamide therapy.
The problem of whether it is a wise procedure to
treat a simple acute streptococcal mastoiditis with
sulfanilamide alone is a difficult one.

Hageman and

Blake (86) have reported that only two of 11 patients
who were treated with sulfe.nilamide for acute streptococcal masto1dit1s required mastoidectorny after sulfanilamide was started.

In nine instances the disease

subsided without surgical intervention.

ThAse men also

recommended the use of sulfanilemlde in treatment of
acute mastoiditis following mastoidectomy.

These men

reported, as well, that only one of nine cases of purulent hemolytic streptococcal sinusitis required surgical treatment after sulfanilronide had been started,
and in this one patient a mixed becter:lal infection was
present.

Other observers (8'7,88) have stated that

they noted favorable effects following the therapeutic
use ofthe drug in acute sinusitis.

These men also
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noted remarkable response of chronic otitis media and
mastoiditis.
Long and Bliss (13) state that they heve had excellent results in trea.tment of cellul1 tis with sulfanilamide.

They show that the use of wet soaks or

packs, es is customary, 1s unnecessary as an adjunct
to the treatment, anoit may do harm because it leads
to abscess formation.

They state that the drug should

be continued until at least two days of normal temperature have elapsed and there is a merked regression
of the local lesion.

Thereafter it should be continued

in lessened doses until recover'T is complete.

If an

abscess is incised, the drug should be continued in
small amounts until the wound has healed.
Hageman and Plake (86), and Mcintosh and Wilcox
( 87) have shown fine results from sulfanilamide therapy
for lymphad.enitis from hemolytic streptococcic infection.
They give lower blood concentrations of the drug than
is usually held for other infections.

It may be

promptly discontinued when the lymphadenopathy hes
receded.

Here again the soaks seem unnecessary.

Hageman and Blake (86) and Fleming (89) first
have shown good results in chemotherspy for hemolytic
streptococcal pleurisy.

Surgical intervention should
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be used only if absolutely necessary, they insist.
There is a

~od

deal of conflict of opinion re-

garding the effectiveness of sulfanilamide against
scarlet fever.

Paul N. Morrow of the University of

Nebraska College of Medicine tells of a very large
series he followed on pediatrics et The Philadelphia
Hospital for Contagious Diseases.

The final obser-

vations were so contusing that the variations could
all be from imperfect stetistical methods.

There was

no tangible improvement under this therapy, either in
course of disease or number of complications.
Mellon (14) discusses scarlet fever at great
length in setting forth criteria

or

therapeutic effici-

ency, with reference to sulfanilamide.

He reminds the

reader of the mistaken impression that once prevailed
concerning the similarity of streptococci.

Workers

then thought that if a serum should be effective against
erysipelas it should also be effective against scarlet
fever.

However, it was soon found that the serum used

for one not only would not work on the other, but the
serum for the erysipelas of adults would not combat
that of the infant, 1n which the mortality from the
diseese ranges from 80 to 90 per centl

He (14) de-

scribes sulfanilamide as a "non-specific serum", going

44

on to discuss the variation in age of the patients
suffering with

erysipel~s

who respond to therapy.

Here

again the error is seen in thinking that sulfanile.mice is a specific chemotherapeutic agent for streptococcic infections.

Once more it must be stressed

that the ability of the drug to act seems to depend
not only on the micro-organism concerned with, but
also on the manner in which the.t micro-organism manifests itself in the morbid process in the body.
Observing this fine variation in strains of
streptococci it is no wonder that reports vary so
much on effect of the drug on scarlet .fever.

The

writings are so voluminous on this sulJject that they
cannot be completely covered

h~re.

It may be stated,

however, that .for every attribute found for sulfanilamide in this instance there is a contrary one.

Sako

and his associetes (90) conclude, a.fter study of an
extensive series, that thA drug should be used

&.t

the

onset of the disease, and, although it does not alter
the course of the fever period, it considerably cuts
down on the number of complications.

On the other

hand, Toomey (91) concludes, after a similar study,

that the drug does not cut down on the number of
complications at all, but should be used if these
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complications arise.

Now, when we can realize that the

drug has no action against most infections where there
is a local problem at hand, we wonder if it cen ue

of any benefit for these complications, since they are
of such a nature in most instances.

Surely, the tissue

destruction in a pharyngeal abscess would prevent any
local action of sulfanilarnide, and it has been previously shown that only part of the cases of otitis
media are of a nature that will slow action of the
drug.

Still, at the same time it was shown that, in

view of occasional benefits, it should be tried in
most cases.
In cases of scarlet fever, surely, if signs of
toxic reaction are met, the drug should no longer be
administered, for there is no indication that sulfanilamide is a very important therapeutic agent.
The introduction of sulf apyridine has brought
many favorable reports concerning its use in combating
pneumococcus pneumonia.

Prior to this development the

benefits derived from the sulfonamide compounds in
treatment of lobar pneumonia were scant and in no way
comparable to the results achieved with antiserum.
Heintzelman, et al (92), offered one of the earliest
works in this line.

Nineteen cases of

pn~umococcus
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pneumonia were reported by them..
ten were used as controls.

Nine were treated and

The pneumonia was of Type III.

Seven of the nine treated cases recovered, and two
dies, in contrast to the ten untreated cases, among
which two patients recovered and eight died.

They

found that if the drug was given early in the disease
the chances of benefit

fr~m

it was better.

A few other

workers (93,94) also gave favorable reports of the use
of sulfanilamide in the

tr~atment

of lobar pneumonia.

However, there seemed to be no evidence that bronchopneumonia would respond.

Evans and Gaisford (95)

were the first men to report the fine response of
pneum.ococcus pneumonia to sulfapyridine.

A hundred

ps. tient a who were suffering with the di see.se were
treated with the drug and a hu11dred others were given
only symptomatic treatment.

There wes no apparent

difference in ages of the two groups or in variance of
the types of pneumococci discovered.

The cases were

all received at the ss.me season of the year and from
the same loca.li ty.

Only 44 of the 200 patients were

successt"uly typed.

The fatality rate in the treated

series was eight per cent, whereas in the other group
the rate was 2? per cent.

Of those patients who re-

covered, 44 had a normal temperature by the sixth
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day in the treated group, while only 20 in thA untreated
series had normal temperatures on. the sixth day.

If

the treatment was discontinued too soon in the course
of the disease, secondary fevers assoc:i.ated with
recurrences or a spread of the pneumonia were noted.
Following this impressive report, there was much
study of chemotherapy for this disease (96-100).

These

papers were not only conrirmBtory in nature, but they
also l):)came increasingly more demonstrative of success,
until now it is frequently a decision to be made-- to
use the drug or the serum.

The journals of the year

1939 carry too much material to describe in the space

here alotted.

Suffice to say that results are about

as good in cases treated with sulfapyridine as in cases
treated with antiserum (101).

Most writers emphasize

the fact that patients should still be typAd because of
occasionally finding one who does not respond satisfactorily to drug administration.

Some recommend use

of both the antiserum and the sulfapyridine.

This use

of sulfapyr1d1ne is far superior to similBr use of other
sulfonamide compounds that have es yet been tried.
(101,102)

As this paper is today written work is being done
with sulfapyridine in treatment of pneumonia.

The
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Omaha World Herald (Tuesday, March 19, 1940) carries
the following Associated Press dispatch:

"New York

'

March 18-- A displav showing a drop of 40 thousand in
pneumonia deaths in the United States in the la.st yesr
will be one of the new exhibits at the New York world's
fair this summer.
"Sulfapyridine, the new medicine for pneumonia,
will be shown as playing an important pert in this great
saving.

l~ether

the surprising drop from 130 thousand

deaths in 1938 to 91 thousand in 1939, was all due to
the new remedy is not yet known.
"Medical reports he_ve p'ointed to the possibility
some or the decrease in 1939 might have been because of
milder types of pneumonia that year.
"However, the exhibit will contain evidence thet
aulfapyridine lest year cured nine out of every 10
persons to whom it was administered."
It is interesting to note that in the

s~me

edition

there is evidence, through the International News
Service, that two persons, one in Chicago and one in
San Francisco, were showing wonderful response to
sulfanilamide administration for ataphylococcic septicemia.
enall

The pace these drugs are setting is phenom-
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One of the most talked of uses of sulfan1lam1de
the last few months is its local

i~plantation.

The

amount of talk, end probably the amount of use of this
nature seems to far surpe ss the 11 tere.ture on the subject.
An obstetrical term ago Jensen, Johnsrud and Nelson (103)
reported local implantation of the drug in compound
fractures with favorable results.

These men treated

39 compound fractures with this local 1r:iplentat1on of
thA drug and as a result found no single primary wound
infection.

Of 94 cases treated in as nearly exact

fashion as possible except for the local implantation, 27 per cent resulted in primary wound infection.
These men pointed out the following factors to be
concerned with here:
dissolve slowly.

Sulfanilamide crystals in a wound

The lest of the drug leaves the body

in about 60 hours.

Marshall, At al (104), showed that

after one single large dose of sulfanilamide, the lEst
of it was excreted by 24 hours.
et al concluded that

th~re

Therefore, Jensen,

must be still some of the

sulfa.nilsmide at the wound site for at lee.st 18 hours.
Th'3se latter men go on to state that the highest
blood level of the drug in their patients so treated
was found in 18 hours.

These latter men go on to show

that since the solubility of sulfanilamide is 0.8
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per cent at body temperaturA, thts concentration of
the drug is prnbeble e.t the wound site.

'fhus a C')n-

centration of 800 mg%' is :ms.intained for a considerable
length of time, wherees only 10 to 2n mg% can safely
be maintained by administrstion per os.

From these

facts it csn be seen that a concentration of 80 times
the me.gnitude is theoretically obtained.

'.rhese men

conclude that th:ls manner of treatment uses a bactericidal effect of' th'.3 sultanilamide for organisms more
susceptible t

J

1

the drug and a bacteriostatic effect

for others.
Jensen, et al did some experimenting with guinea
pigs in the following manner.
animals.

The7 used seventeen

Seven were used as controls.

In the controls

they fractured a rib with scissors through a wide
incision, end in the other ten 0.5 gm of sulfanilamide
was implanted in similarly produced compound fractures.
Five out of the sevan controls had primary wound infection, while seven out of the 10 of the others healed
uneventfully.

Of the ten treated animals it is of

note thbt one of the three which suffered infection
was not closed tightly, to observe the effects if

th~

drug could fall from the wound, and another of those
infected had had blood dravm f'rom 1 ts heart at frequent
intervals.
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Jensen, et a.l conclude from their fine study
that, "The local use of sulfe.niledde has open1d the
way for more effective treatment of contaminated
wounds.

The amount to be used in each specific wound

depends upon the extent of trauma and contamination."
They recommend 5-20 gm (no more), and show the necessity of painstaking de bride men t •

rrhey

i)e lieve the

drug only bacteriostetic against staphylococci, even
in concentrations approaching one per cent.
Since the work of Lockwood and Lynch (34) with
peptone broth it will be interesting to see further
work in this line.

Lockwood and Lynch show that a

concentration of sulfanilamide must be a.bout 100 times
that of the products of protein catabolism before there
is therapeutic effectiveness.

Work is therefore

warranted in these higher concentrations.

The con-

centration of pei t;;ne in the tissue :fluids at a wound
site

CD

uld easily be 10

mg~~'

and if this concentration

were reached the concentration of 800 mg% of sulfanilamide would be insufficient.
This would encourage complete debridement as
recommended by Jensen, et al (103).

On the other hand,

it seems there has been evidence (before presented)

that certain instances '.'There there is a small degree
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of tissue damage as in otitis media, certain cPses of
cellul1t1s, and such, there has been a favorable
response to sulfanilam.ide.

This brings out the point

that a line must be drawn somewhere showing the degree
of tissue destruction that is necessary before any
beneficial response is possible.

It also shows that

the drawing of this line, as with the drawing of similar lines in medicine, is practically impossible.
Since the wound infections are here non-specific, the
non-specificity of our drug is again seenl
The attributes of local implantation are highly
feasible.
inadequate.

Study of effects for guidance of use are
Since a wound is easily seen for study,

it is not believed ostentatious to think that this
pharmacologic study is necessary.

Since sulfa.nil-

amide is taken up by the body tissues without e.pparent
damage to them, is it possible that here is a satisfactory antiseptic?

The action is above stated bv

Jensen, et al to be bacteriocidall
Clostridi"m welchii infections have also brought
considerable comment in the last year.

Early in the

history of sulfanilamide, Bohlman (105) reported
three cases of gas gangrene which responded wonderfully to sulfanilamide administration within 24 hours.
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This finding was apparently confirmed by Kennedy (106).
Sadusk and Manahon (107) report two cases of
poatabortal Clostridium welchii infection with positive
blood cultures in which the blood stream was rapidly
sterilized by the use of sulfanilamide and the patients
recovered.

They also carried out some experiments and

adequately showed the bacteriostatic action of sulfanilamide on Clostridium welchii in vitro.

Such action,

th9y showed, was inversely proportional to thA number
of organisms used as

th~

1noculum.

Ne are taught that patients who succumb to gas

1

gangrene in the first week are overcome with the great
toxicity of the organism.

fiowever, it is seen that in

the second week the fatalities are from septicemia
arising from secondar;r infection.

Whether the Clos-

tridium welchii, which is seldom the etiologic factor,
per

~

of the septicemia, is in the blood streem or

some other organism, it is undoubtedly e. most ideal
occasion for use of the drug, for more each day it is
shown that sulfe.nilamide takes care of a multiplicity
of septicemias.

What could be more id,3al for admin-

istration of the drug than a generalized infection
too acute for tissue destruction, no matter what the
etiologic factor, within certain limitsl
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In reviewing th(3 therapeutic effects of sulfanilamide as just related, the inadequacy of th9trsat1se
is seen.

New developments are constantly appearing.

Those now coming t

1
)

the foreground seem to be dominant-

ly of treatment of different infections than heretofore attacked.

Staphylococcus infect ions, bacillus

infections, subacute-bacterial-endocarditls, and even
the tubercle bacillus

ar~

now being approached.

In

its entirity we are again reminded of the extreme nonspecificity of the sulfonamide compounds and of their
confusing action.

The manner in which these therapeu-

tic effects hook up with cellular metabolism and catabol1am in the body and the metabolism of the bacterial invader, must not be forgotten in this mad
scrambls for blinrJ cure, lest physiology suffer in the
wake.

TOXIC 4:FF?.CTS
Any one who gives sulfanilamide should be acquainted
with the toxic effects of the drug and the severity to
which each individual toxic reaction can extend.

For

this reason these effects will be classified according to severity.

This method of classificetion has

been used by many writers for reason of its practical-
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nass (36,108).

Generally these effects are put in two

groups, one group of those which are common and seldom
severe enough to cause alarm; and another of those
which are rare but dangerous and contraindicate continuance of treatment.

This is a fine way of think-

ing of these reactions, however,

th~

grouping is still

more adequate if a third group is inserted.

The

composite picture might result in the following outline:
MILD TOXICITY (Jt,requently se3n, but usually
do not require discontinuance of the drug.)
Moderate cyanosis.
Anorexia, nausea.
Dizziness, headaches, tinnitus, slight mental confusion.
Weakness, fatigue.
SYMPTOMS OF

MODRRATE TOXICIT~! (Call for close observation, but do not call for the discontinuation of
the drug when it is very much needed.)
Vomiting, sense of oppression.
Cyanosis or mild dyspnea.
Mild, slowly developing anemia.
Dierrhea and abdominal pain.
Yild rash or itching.
Paresthesia, diplopia.
Acidosis.
Slight fever.
SYMPTOMS OF

SYMPTOMS OF SEVRR~

TOXICI7Y (Call for the immediate
discontinuation of the drug and corrective measures.)
Drug fever.
Tachycardia.
Leukopenia.
Jaundice.
Acute anemia.
Dermatitis.
Psychosis, or disorientation.
Albuminuria, hematuria.
D1plopia.
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This outline will not always be a true guide to
severity of a toxic reaction.

People who have taken

the drug may often sey that the nausea with the administration can be of an intolerable nature.
Patients taking the sulfonamide compounds should
undouotedl;r be in bed during the course of treatment,
not take other medicine unless absolutely necess8ry,
ano should probably not enter any high altitude unless
required (?).
Cyanosis is so often seen in the course of therapy
that it is generally disregarded.

It is an erroneous

belief that it should be present before therapeutic
effect can be foundJ

Long and Bliss ( 13) state,

"In our experience, cyanosis has not been an alarming
toxic manifestation and cen genArally be disregarded.
We have noted its appearance following the administration of n.o of a gram of sulfanilamide, and, on th"
other hand, we heve seen patients who were receiving
large doses of the drug in whom cyanosis was minimal."
Ey large dos2s it '.•1ould be assumed that Long and .2liss
meant large doses, for they have done superior work
with the drugs from all angles and insist upon high
blood levels l

They go on to de scr1.be the "black" or

"brown" color that either arterial or venous blood
assumes.

When this blood is shaken or bubbled with
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oxygen it does not regain its normal color.

When

sulfanilemide therepy is stopped, however, the darkness
disappears and the normal color of the blood is assumed.
The only writers who agree on the origin of the
cyanosis are those who attribute it to about three
factors. ( 109, 110)

These men state ths.t both sulf-

hemoglobinemia and rnethemoglobinemia result as well as
the formation of an unknown pigment.

They both agree

thet the methemoglob1nem1a is dominant.
have attributed the cyanosis to

th·~

Some workers

formation of

sulfhemoglobin predominantly (24, 110-113), some
attribute it more to formation of methemoglobin (110,

111,11•-117), and some attribute it to an unknown cause,
possibly by a discoloration or the red blood cells by
a pigment formed in the course of sulfanllamide therapy
(115) or to reduced hemoglobin (118).
Chesley (117) concludes af'ter his study that he
had successfully ruled out the formation of sulfhemoglobin and methemoglobin in eight cases showing extreme cyanosis.

Bigler and Werner {119) conclude that

the "cause is still not clear. -- -- -- Only in some
instances has spectroscopic examination of the blood
revealed presence
bands.

or

sulfhi3moglob1n and methemoglobin

-- -- -- Also the cyanosis does not seem to
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depend on oxygen saturation of the arterial blood."
These men also agree with Long and Bliss (13) in that
the cyanosis does not seem to depend on the age of the
pRtient, deily dosage or the length of ti:rie

th~

drug

is administered.
Colebrook and Kenny (24) attributed a great deal
of the cyanosis to concurrent use of magnesium sulfate
as a cethertic during prontosil adm1n1stretion and
advised its immed1ate sessation.

They did not :recommend

cutting down on sulfur-containing foods or drugs, but
did encourage diets that would produce a minimum of
hydrogen sulfide in the lower powel.
Archer and Discombe (120) believe thst the cyanosis is a. sign of approaching danger end insist the.t
regular blood examinations should be ma.de of all who
are cye.notic.

It will be shown below, however, that

this should be done in all

tr~sted

patients.

The use of methylene-blue in combatjng the cysnosis
was originally suggested by Hauschild (cited by 121),
advocated by Wendell, and favored by Hartmann, et al
( 122).

Camp be 11 and Morgan conclude ( 121):

" ( 3) In

methaemoglobinaemia, whether produced by 2 p-aminobenzenesulphonemideopyridine or by sodium nitrite, methylene-blue is effective in causing the rapid disappear-
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ance of the cyanosis by converting methaemoglobin to
hemoglobin.
" ( 4) ThA dye is active when given intravenously,
intramuscularly or by mouth.
n(5) It is suggested that routine employment of

methylene-blue in conditions calling for the prolonged
administration of sulfapyridine may be a useful measure
preventing cyanosis.
11

(6) Methylene-blue has no effect in preventing or

modifying cyanosia of sulphaemoglobinaamia."
Treatment of the cyanosis truly would rest the
patient from possible anoxemia.

Although methylene-

blue seems good its scope in prevention and treatment
is limited.

The various abnormalities of the blood

pigment produced by sulfonamides is not fully understood.

One to two mg per kg of body wt IV or one to

two gr (65-130 mg) per os, given every four hours is
quick to bring and maintain response from rnethemoglobinemia.
Cyanosis deserved special early

treatm~nt,

for it

is the stands.rd upon which so many toxic manifestations
of the administration of the drug E:.re based.

Many of

these unfavorable reactions may· be correctly paralleled to the color of the patient, so to speak, but many
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of th:;se findings indicate possible further severity
along similar lines.

.As in cases of congenital ano-

malies, w'h3re one is !-re sent alwsvs baivare of another.
A mild dermatitis

ms~r

be indication of approaching

jaundice or agranulocytosis for often these manifestations ere multiple.

In the same fashion one who has

had mild toxic rP-action during one course of therapy
may be the victim of a more severe episode during a
ls.ter course.
A good example of this multiplicity of similar

reactions is

se~n

in the nervous system.

Those who

frequently administer the drug are familiar with the
nausea., dizziness, headaches, tinnitus, and even slight
mental confusion that frequently accompany early days
of therapy.

Some, on the othAr hand, offer reports

of rather severe cases of toxic peripheral neuritis
(123,124).

It is of note that these reports deal es-

pecially with some of the newer deriv&tives.

Perhaps

this effect :ls more peculie.r to one of these newer
compounds than it is of the more established drugs.
Mild mental disturbances sre not uncommon in p&tients
who are receiving sulfanilamide.

Many individuals

complain of feeling depressed, although occe_sionally
the drug causes elation.

Frequently, the ability to

concentrate upon a given problem is disturbed.
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Frank disorientation is uncommon, although mild confusion is often seen.

Hallucinations, both auditory e.nd

visual, he.ve been noted.
ally occurs.

Mania is rare but occasion-

Hogan and McNamara (125) have described

a toxic psychosis which developed in a patient during
treatment with

th~

drug.

Following tbA removal of the

drug the patient showed a steady improvement.

Danziger

( 126) observed e. patient who twice had a toxic res.ction,
characterized by cyanosis, confusion, and negativism,
which occurred in each tnstance four days after sulfanilamide therapy had

be~n

stopped.

The mechanism of

this reaction was considered to be unknown.

It is

obvious that in certain instances it is very difficult
to distinguish between the abnormal

m~ntal

reactions

frequently noted in the course of sever(:; acute febrile
inf'ections, and those due to sulfanilamide therapy.
Early in the history of the drug several specific
cases of neuritis were observed.

A rather severe toxic

optic neuritis was reported in 1937 (127).
Recently two ceses of encephalomyelitis following
the administration of sul.fanilamide were descril;ed,
one of which ended fe.tally {129).

The total doses taken

were small ( 14 gm anrl 18 gm) and if the drug was responsi (;le the patients must have been more than or-
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dinarily susceptible to it.

Vascular changes were seen

in some of these cases of enoephalomyelitis and their
relation to the demyelinating lesions was discussed.
These men offered evidence that patients suffering from
certain illnesses, including acute rheumatic fever and
lupus erythematosus, are especially liable to develop
toxic manifestations aftentaking sulfanilemide.
Tachycardia is sometimes observed, and not infrequently only apparent because of the obvious cyanosis
which is so often present.

Also the tachycardia may

be blamed upon the changes in the blood stream by methemoglobin and sulfhemoglobin formation.

Dazzi (128)

presents a case which might establish the likelihood
of cardiac damage resulting from the use of sulfanilamide.

In this case there was a transient nodal

rhythm following use of the drug.
Long and Bliss (130), and Dees and Colston (131)
offer undisputable evidence that a febrile reaction
frequently occurs during administration of sulfanilamide.

Since these works many more reports of a febrile

reaction have been offered (32,133).

These men all

impress the reader with the contusion that may arise in
diagnosis when this foreign fever occurs.

Hageman and

Blake (132) noted the freauent occurrence of a fever
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reaction along with a toxic dermatitis.

Gallagher

(133) analyzes the fevers which he observed and concluded that this reaction was probably based on idiosyncracy similar to that seen by other observers in
other toxic manifestations of the drug therapy.
An interesting case of severe drug-fever was recently presented in the literature (133).

The patient

underwent a 12-day course of sulfanilam1de therapy in
1937.

During this course the patient developed a

morbiliform rash and general malaise.

In 1939 there

was again reason to administer an e•tensive regieme
with the drug.

The patient was to have four 20 gr

doses on the first day.

After the second dose general

malaise, headache, cyanosis, chilliness and fever were
evident.

The drug was stopped immediately, but the

temperature of the patient continued to rise.
were forced.

Fluids

On the second day, although the drug

was no longer admlnistered, a rash became prominent.
It was of a morbilliform nature as it had been in the
previous course.

The temperature reached 104 degrees

by the end of the second day, and the white blood
count dropped from 17,000 to 9,000 in this short
interval.

on the fourth day the patient was again

comfortable and afebrile.

The rash gradually faded.
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Long and Bliss (13, page 2'75) state, "')ur experience with this toxic manifestation (fever) of
sulfanilamide therapy has been essentially that of
Hageman anc'l Blake.

~.,e

have noted drug fever occurring

as early as two hours andas late as twenty-one days
after the institution of sulfan1lsmide, although the
usual time of appearance of drug fever is between the
fifth and tenth days of treatment.

In our experience

9 per cent of adults and 3 per cent of children develop
drug fever in the course of sulfanilamide therapy.
We have also noted that fever may be the initial sign
when a serious toxic manifestation such as hepatitis,
acute hemolytic anemia, or agranulocytosis is developing.

Because of such observations we have come to the

conclusion that fever constitutes onB of the most
important warning signs in the course of sulfanilamide therapy, and feel that the physician must "atop,
look, and 11 s ten'' when drug fever develops. "
Foreign writers (13} have done much in the study
of the effects of sulfanilamide on spermatogenesis.
There seems to be no conclusive evidence th.at it is in
any way damaged.
The dermatitis that has been so frequently re-
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ported as e toxic manifestation of sulfanilamide administration, is peculiar.

~arly

in the use of the

drug it wbs noted that patients exposed to sunlight
were especially affected.

Since the great majority

ot patients who were ambulatory and most frequently
exposed to sunlight were those suffering from gonorrhea, it was at first thought that there ws.s some
connection between this disease end the drug administration.

However, this has been discredited.

The

literature on this phase of toxic effects is voluminous
(134-142).

The rash has been described as exfoliative

(139), purpuric (141), morbilliform (134), varioliform
(135), and urticarial (136).

Some workers have noted

a peculiar stomatitis eoncomittent with the exanthem
(136,138).

They described these oral lAsions as being

similar to mucous patches of secondary syphilis.

This

would be good to remember in diagnostic examination.
Schwentker and Gelman (144) first described the
rash.

They stated, "It is distinctly morbilliform in

character, made up of maculopapular lesions slightly
raised from the surrounding unaffected skin and brownishred in colour; although it does not fade completely
when pressure is applied, the blanching of the rash is
considerably more marked than that seen with a typical
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measles eruption.

TJsually almost the entire surfe.ce

of the body is affected, but in some cases the rash
has been limited to the buttocks or the legs.

In some

of our patients the eruption was seen on the palms of
the hands and the soles of the feet while the mucous
membranes were apparently unaffected.

There was no

itching or other abnormal sensation et the site of
the lesion.
"The rash usually develops rapidly without any
prodromal symptoms, the entire evolution occupying
only about 12 hours.

Fever, and general malaise have

always been present and have sometimes preceded the
eruption by several hours.

The temperature rises sud-

denly, usually ranging between 101 end 103 F., and
then drops to normal gradually over a period of 2 to 4
days.

The malaise disappears with the fever.

symptoms have been observed.

No other

The blood count shows

no significant alteration.
"With discontinuance of sulfan1lamide therapy
the eruption fa.des rapidly and :ma.y disappear completely.
If the sulfanilamide treatment is not discontinued the
time of appearance of the primary rash, the eruption
fades and disappears completely in abm1t seventy-two
hours."
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Schlesinger and Mitchell (134) offer a good summary
of dermatitis which we are here concerned with.

They

also described many cases, among which were ten in
children.

They state that the eruption usually is

first seen in five to seventeen days after original
administration with continuation.

In their series it

was generally preceded by a leukopenia.

An

"natural history" of the eruption was given:

interesting
First

a prodromal period was noted with a fever and transient
leukopenia, enrl following this the rash appeared, often
with splenomegaly.

A few days after the drug was

stopped the rash started to gradually fade in most
every incident.

Schonberg (141) points out the manner

in which the rash can easily be confused with that of
scarlet fever.
An interesting case of delayed photosensitization

has been recently presented (140).

In this

~aper

it

is stated that photosensitization of the skin due to
sulfanilamide is a relatively rare occurrence, but
should be carefully guarded against because of the
increased use of the drug.

The case reported is

unusual because it illustrates delayed photosensitivity
of the skin brought on many months ar'ter therapy was
started and discontinued, due to exposure to sunlight
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and artificial sunlight.

These photosensitized areas

were large deep, dark brown patches, apparently fixed
in the skin, with a sharp line of demarcation, occurring after withdrawal of the aulfanilamide.

Some of

these areas broke down and caused troublesome ulcers.
It was emphasized that patients taking sulfanilamide
should be strictly warned against expostmg themselves
to sunlight or artificial sunlight during or after the
taking of sulfanilamide.
From this multiplicity of manifestations in the
skin, it is seen that no definite dermatitis can be
watched for.

If one does occur, however, one should

be certain of its origin, and should watch for other
toxic reactions.

Then confronted with such reactions

11

the drug should be discontinued only if it is not an
essential part of the therapeutic

regi~me,

but if con-

tinued, daily blood counts should be made and other
key-signs watched forJ
With the use of aulfapyridine increasing every
day, and our satisfactory understanding of the precipitation of a cetyl-sulfap;rridine in the kidney ( 145),
an oportunity for dramatic action is occasionally
offered the alert urologist.

This is beautifully

exemplified by Carroll, et al (146).

These men had a
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case of complete anuria following the administration of
sulfapyridine and, wisely, they did a cystoscopy,
lavaged the ureters with warm water, and the patient
rapidly recovered.

The first of their conclusions well

summarize the story and i ta le saons:

''1.

The super-

saturation of acetylsulfapyridine crystals during the
administration of sulfapyridine is sufficient at times
to cause a complete obstruction in the urinary tract.
11

2.

This condition can be promptly and satisfac-

torily relieved by cystoscopically inserting catheters
in the ureters

and~elves,

and lavage with warm phys-

iologic solution of sodium chloride or sterile water.
"3.

These crystals, even in large amounts, which

cause obstruction, are not opaque to the x-rays; therefore a flat roentgenogram is of no value.

Thf~

symptoms

of kidney colic and/or hematuria should make one suspicious of crystalline concretions in the urinary
tract and should not be mistaken for gastric upsets.
"4.

The hematuria noted clinically is probably

the result of minute traumatism of the mucous membranes
by the crystals rather than damage to the renal parenchyma and therefore is of no grave consequence.
11

5.

The forcing of fluids in conjunction with

sulfapyridine therapy is probably appropriate, since
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it will relieve the supersaturation of the urine to
som9 extent."
To be sure, the inert salt of sulfanilamide is
also precipitated in the urinary tract if the concentration is great enough, however, this is unlikely
since the inert form is not nearly so dominant in the
blood stream or in the urinary tract as it is with
sulfapyridine {14?).
Much experimenting has been done with porphyrinuria in rats, both with sulfanilamide and with related
compounds (148,149).

Oakley, and Bensley and Wilen

have well emphasized the dangers in administration of
the drug in the face of renal damage (150,151).
Bensley and

~vilen

showed the gravity in delayed sulf-

an1lam1de excretion in a case of pneumonia with renal
failure.

Ravel and Curtis (152) emphasize the serious-

ness of hematuria and abdominal pain associated with
sulfapyridine administration.

Many other workers have

been concerned with the formation of urinary calculi
here (153,154).
Concern will n0xt be directed to the apparently
most grave toxic manifestations of sulfanilamide, namely
acute hemolytic anemia, agranulocytic angina and
hepatitis.

The fatalities accredited to the drug are
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practically always in this category except for a stray
case of anuria or such now and then.
Harvey and Janeway (62) offer the first report of
acute hemolytic anemias, characterized by a sudden
onset with a marked drop in hemoglobin and red cells,
jaundice, disturbed liver function, urobilinuria, or
in severe cases, hemoglobinemia and hemoglobinuria,
marked reticulocytosis, and leukocytosis.

They described

three cases, all showing these similarities.

In each

incidence the extreme anemia seemed to develop in less
than 48 hours.

Later in th&same quarter Kohn (155)

gave similar evidence.

Since that time there have been

numerous similar reports (156-158).

Wood (158) re-

ported 21 cases of acute anemia which developed in
patients who had received sulfanilamide in the johns
hopkins Hospital.

He noted an incidence of acute anemia

of 8.3 per cent in 144 children and 2.4 per cent in
378 adults.

No predisposing factors were noted in the

analysis that Wood made of these patients, but he did
find that all of the patients who developed acute anemia
had fever at some time during the period of sulfanilamide
therapy.

No relationship to dosage, concentration of

the drug in the blood, or acidosis was observed.

In

all of the 21 cases the fall in hemoglobin was shown to
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begin between twenty-four and seventy-two hours after
treatment was started.

The time of maximum anemia

occurred between the third and seventh days, with the
greatest number of patients (nine}
anemia on the fifth day.

develo~:ing

maximum

Nausea and dizziness were

found to be the earliest symptoms of an approaching
anemia, while fever and an increased urobilinuria were
the earliest signs of the toxic reaction.

One or

more transfusions were needed to combat the anemia in
13 of the 21 reported cases.
died.

None of the patients

Free hemoglobin was demonstrated in the serum

of at least one of Wood's patients.

Four of the 21

patients were subsequently given sulfanilamide for
therapeutic purposes and three of them developed acute
hemolytic anemia.

The patients were subsenuently

gliven sulfanilamide for therapeutic purposes and three
of them developed acute hemolytic anemia.

The patient

who escaped anemia did not have fever at the time of
the second course of the drug.
Several workers have found that there is an
increased reticulocyte count accompanied by a moderate
decrease in the hemoglobin and red blood cells in
patients who were being treated with sulfanilamide
( 159 ,160).

Long and Bliss state (13), "Our own experience
leads us to believe that sulfanilamide produces a mild
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hemolytic anemia in many individuals.

This is es-

pecially true if traatment with the drug is prolonged
over a period of several weeks.

These anemias are

characterized by a slow, but progressive, drop in the
hemoglobin and red blood cells, a moderate reticulocytosis, and often a mild urob111nuria.

Anemia of this

type is not to be feared and does not constitute a
contraindication to further therapy.

If the hemoglobin

drops below 60 per cent and further treatment with the
drug is n(;eded, a transfusion is indicated.

However,

if at this point the drug can be stopped without fear
of a recurrence of the infection, the blood rapidly
regenerates."
Agranulocytosis in its apparently limited variations is undoubtedly the most serious of the toxic
manifestations.

A very pathetic picture is painted

by the literature of this quite sudden death, suffering
with severe angina in most instances.

Thia manifes-

tation has been attributed to Prontosil, Neoprontosil,
sulfanilamide, benzyl sulfanilamide, sul:t'e.nilyl dimethyl sulre.nilamide, and sul:t'apyridine (161-177).
The general effects of sulfanilamide upon the
white blood cells in general have been studied at great
length.

Bigler et al (119) attempted to show that there
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was generally a marked depression of the number of white
cells.

In some instances, these men state, the depres-

s:!on hinges upon being a leukopenie..
found the lower lirrits of their

vi 1

However, they

hi te blood counts

to be a.bout 5,000 per cubic millimeter, and they
admitted that part of the decrease was apparent since
the white cells were not fewer in comparison to other
cellular blood elements.

Campbell (159) did not find

any effect of sulfanilamide upon the white blood cells.
Hedicl extensive studying on the subject, which is not
yet closed by any means.
Agranulocytosis has been known to occur in intoxication with various other drugs.

Dinitrophenol,

amidopyrine, allonal, and novaldin have been known to
produce a similar picture, although the severity seldom
approaches that of the reported cases with sul.fan1le.m1de
intoxication (162).

No correlation between these drugs

has been seen.
Jennings andSouthwell-Sander (160) present a very
interesting case in which there was both agranulocytosis and a pro.found anemia.

J)olgopol and Hobart ( l '75)

suggest that blood counts only be done twice a week.
They point out that in most of the fatalities reported,
no blood count was done in the interval of development
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and that if such was watched twice a week regularly,
the development would no doubt be seen.

Most men,

however, agree with Borst (165), in his early article,
where he emphasizes that to avoid these fatalities
daily blood counts and observation of thro&t is necessary.
Not only granulocytopenia but also hyperleucocytosis
has been attributed to sulfanilemide and allied
compounds (177).
Borst (165) reported one of the earliest cases of
fatal outcome.

He attributed this death to

th~

ad-

ministration of not more than 1.8 gm of prontosil daily,
although the patient's previous history may have indicated some predisposing disease of the bone marrow.
This investigator decided, in view of the number of
severe toxic reactions concomitant with his use of
prontosil, to treat subsequent patients with sulfanilamide.

Since that time, the number of severe toxic

reactions concomitant with the use of other derivatives
of sulfanilamide and sulfanile_mide itself have been
quite well balanced.
Young (1?8) reported another of the early cases of
agranulocytosis with fatal termination.

His was in a

case of acute rheumatism which, following the failure
of salicylate therapy, had been treated with 3 gm of
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sulfanilamide daily for 18 days.

Treatment was dis-

continued at this time because the clinical condition
of the patient was frankly worse.

A blood specimen

taken f'our days later showed complete agranulocytosis
and positive culture for hemolytic Staphylococcus aureus
and Streptococcus viridans, although a negative blood
culture had been reported three weeks earlier.
occurred on the following day.

On~

Death

the day prior to

death the blood showed 1,880 lymphocytes and no leukocytes.

The author believed the agranulocytosis to

be either of the-idiopathic t:vpe of unknown etiology
or to be due to sulfan1lam1de therapy.

Other cases,

reported in the opening paragraph of discussion of this
toxic effect, are quite similar to these two.

The

dosage varies within certain limits, being quite small
in some cases.

The onset of the depression of the

white cells is also not always spaced the sam0 from
the day of onset of therapy, but in genr-iral, the depression starts in from two to five days.

Young's

case, above described, is an exception in that it
apµerently took over two weeks for the agranulocytosis
to develop.
Reletions to bone marrow disease and-sept icemil!
as above shown in two cases, brings up the question
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of whether or not to use sulfenilemide and its derivatives in the control of sepsis with secondary agranulocytosis or in sepsis

granulocytopenia that

followin~·

is induced by other drugs such as before

m~ntioned.

Again Long End Bliss ( 13) may be turned to for supremA
opinion.

They state, "1ie think that in patients suf-

fering .from egre.nulocytosis and streptococcal sepsis,
therapy with these drugs is not only indicated, but may
be life-saving."

They also advise, for other cases of

agranulocytosi s from sulf'anilamide, "The first step to
be taken when egrenulocytosis develops is to provide
for the rapid elimination of the drug.

Fluids should

be forced vigorously by the peroral and, if necessary,
by the intra.venous route.

The diet is unimportant,

except that it should have a high v&tamin content,
espeoially of vitamin C.

This may be reinforced by

the daily intravenous injection of 500 milligrams of
cevitamic acid.

If angina is a prominent symptom, the

throat should be treated by the topical application
of sodium perborate or neoarsphenamine, there being
no indication that the use of either of these drugs is
dangerous in this condition.

He are inclined to think

1

that the less a patient suffering from agrs.nulocytosis
is disturbed by misguided attempts at palliation, the
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better.

There is scant evidence that nucleotide

preparations are of value in this condition and we
never advise their use.

Transfusions also should be

avoided unless the hemoglobin drops below 60 per cent,
since transfused blood is of questionable therapeutic
value in the absence o:f a definite hemoglobin det'icit.n
Hageman andBlake (130) and Long and Bliss

(L~2)

were early to report jaundice as one of the toxic manife ste. tions of sulfanilamide therapy.

'I'he'j'de scribed

this as !)eing o:f a mild nature and did not e.ttach much
significance to it, except that it represented some
sort o:f liver damege, the extent of which was not
understood.

Long and Elisa associated this jaundice

with marked decrease in liver function in some instances.
They also noted that therA ws.a no acute hemolytic anemia
in the patients observed, for as before stated a jaundice is folmd in those cases quite often.

Other

workers were quick to verify these reports (49, lry9182).

These men also reported cases of extreme hep-

atitis with fatalities.
The ce.se presented by Cline {181) is diff'erent
from the others in t:hat 1 t was an acute yellow atrophy
in the course of sulfanile.mide therapy.

The patient
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had been given the drug over a period of two months,
and at the termtnation of theperiod it was found that
he had been taking it far in excess of th&physician's
orders.

The cese gave many diagnostic troubles.

waa at first thought to be a catarrhal jaundice.

It
There

was no rash present as found in some other reported
cases.

The illness from the drug covered a period of

ten days and ended fatally.

The signs of liver insuf-

ficiency gradually progressed during this period.

An

autopsy was done, and the typical findings of acute
yellow atrophy were recorded.
Bann1ck and his associates (179) have reported two
instances of fatal jaundice in the course of sulf·anilamide therapy.

They, however, attributed only one

of the deaths directly to the drug.

Saphirstein (180)

described an e.xfolie.ting dermatitis and acute hepatitis
in a patient who received aulfanilamide over a period
of seventeen days.

The dermatitis and hepatitis

cleared within two weeks.

Garvin (182) has observed

five patients who developed a toxic hepatitis in the
course of, or subsequent to, sulfanilamide therapy.
In four of these, the hepatitis was considered definitely to be a toxic reaction to the drug.

Two of the

patients developed jaundice and hepatitis while receiv-
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ing the drug.

In the other three sulfanilamide had

been stopped four, seven and thirty-five days before
evidence of liver injury became apparent.

An exfoliat-

ing dermatitis was associated with the hepatitis in
three patients, one of whom died.

There was no reason

to suspect the existence of previous liver damage in
any of these patients.

One patient had previously

suffered from a toxic reaction to sulfanile.mide.

Other

reports have been published of fatal toxic hepatitis
from drug ad.ministration (183,184).
Charles P. Baker, M.A., M. D., o:f the University
of Nebraska College of Medicine, offers the following
case for analysis.

The patient was admitted to the

Methodist hospital, Omaha, Nebraska, on August 16, 1939.
History: Caesarian section for full term baby 2-20-39.
past 15 years "colitis" which consisted of gas pains end
belching. This we.a relieved during the pregnancy.
Two weeks ago joint pains with s vollen tfoints. Patient
treated with sulfanilamide. Following this noted
nausea, dizziness, faintness and confusion. Four
days ago first noted yellow tinge to skin. Has had no
abd:cminal pain but says upper abdomen has been tender.
Following the jaundice joint pains have been relieved.
Physical examination: Skin markedly yellow.
in right upper quadrant.

Tenderness

Laboratory: Hemoglobin 84~, 'J'IBC s,ooo. Urine-- bile
present. Stools very light with bile present in small
amounts occasionally. Van den Bergh immediate direct
reaction. Serum bilirubin 18 mg~.
Course:

8-21-- Hb

?5~,

RBC 3,?50,000.

Stools slight
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test for bile. Serum bilirubin 15 mg~. ~dema present.
Given transfusions.
8-23-- roentgen studies. No calculi found. Liver not
enlarged.
9-14-- serum bilirubin 31 mg%. Considerable ascites
found. Total serum protein 4.5 mg%.
9-20-- serum bilirubin 15 mg1,.
9-27-- paracentesis.
9-30-- serum bilirubin 14 mg%.
10-2-- irrational.
10-3-- dd.
An

autopsy permit was obtained.

found to weigh only 750 gm.
open.

The liver was

The ducts were entirely

The organ was firm, and nodular in appearance.

In microscopic section some post mortem change was noted
in the liver.

The connective tissue was greatly in-

creased in amount, in some regions being the only tissue
present except for compressed bile ducts.

Most all

of the paranchymal tissue was more or less completely
degenerate.

~owever,

in one area there was fine evidence

of attempted regeneration.

Here the cords of cells

were fresh in appearance, arxl they were arranged in
irregular formation about central veins which were not
well centered.

No other significant finding was

apparent.
In considering this case it is noted that the
toxicity hed overwhelmed the restorative powers of the
liver.

No doubt the liver of one person is different

in its regenerative powers than that of another.

The
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great predominance of degeneration over regeneration in
this specimen shows the failure of this restorative
power here.

Sections of the bile ducts were taken at

many levels to be assured th8t no obstruction had been
present.
the story.

Previous liver damage :Ts not in evidence in
The fact that the patient had had previous

toxic reaction to sulfanilamide showed the apparent
idiosyncracy to the drug which here seemed to be
present.
The edema of this patient was no doubt due to two
great f'actors:

Through the intir::ate relationship of

the liver with the protein metabolism of the body the
protein level of the blood was considerably reduced as
shown by the periodic laboratory studies.

With the

great contraction of the liver which was evident at
autopsy it is easy to understand that considerable
portal obstruction must have been present.
No other drugs are known to have been administered
to the patient in this case, and apparently only the
usual dosage was taken over a period of about ten days.
The difficulty in diagnosis here emphasizes the
fact that many of these cases could easily go unreported.
The intimate hook up with protein metabolism is here
again suggested by the liver reaction in the nature of
an idiosyncre.cy.
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SUMMARY

In the statement of purpose of this paper it was
said that an attempt would be made to find

som~thing

in connnon with the effects of sulfanilamide and all1ed
compounds, as interpreted from the literature on the
subject.

It is felt that an important generality can

now be, not made, but only

e~phasized.

This generality

concerns not only the therapeutic erfects, but also
the toxic manifestations of drug administration as well.
This gross impression is seen in most all of the late
11 terature, e.nd can

of the earliest.

:~asily

be round between the lines

This one ract-- that in deciding

where to use the drug, why, and when, what to watch for
in the giving, how to watch for it, why, and when,
and if it comes, in many more relatives-- it is not the
micro-organism that is concerned, the concomitant
morbidity that may be present or the fear of reaction
that is to control and guide therapy-- it ls the manner
in which these m1cro-organisms manifest themselves in
the body, the ability of the body to standany mild therapeutic measures, and the response to those measures
as interpreted by a fair knowledge of what to expect.
During the affair with Massengill and Company,
before mentioned, a layman, or even many students of
medical science, might have said, ''That is sad-- so
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many people meeting death because of this new drug,
but it is e wonderful discovery.
credit for that."

Ne must give the men

1

Few even realize that the early

history of the drug was not even American!
misinterpretation, that has followed the

In

th~

same

developm~nt

of

our collective knowledge of the drug, it is noted that
the first report of therapeutic action of the compound
was es acting against a staphylococcus infection in
man (septicemia).

Still, this was not heeded because

the first proof of therapeutic activity was in experiments with streptococci-- experiments that, incidently, don't work in the laboratory with the staphylococcus.

However, the professional world wes quick

to assume that the drug was e specific for streptococci.
It is only now coming to light thet
micl'o-organisms are affected.

F

multiplicitv of

Staphylococcus septicemias

can be treated quite as well as streptococcus ones if
they are sttacked at a similar stage in the disease
process where

ther~

is parallel tissue destruction.

In the same wav, through the few years of active
history of the sulfonamide compounds, we turn from the
remarkable work of one man to that of another, forgetting to retain that of the first.

The literature

has been too profuse and voluminous for gen·'lral study,
but soon each practicing person will have read at
least one of the frequently appearing short summaries
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that are now seen, and a mora representative impression
will be almost universal.
Dangers are seen in the mistaken impression that
the drug is more or less a specific for streptococci.
General use in sore throats is seen to be harmful as
before shown, and at the same time an important opportunity to save a life may be missed by harboring
this belief.

These opportunities may arise in the face

of concomitant morbidity which may have to tJe bucked,
but a thourough understanding of what is being bucked
to affect must be realized.
Intimacy with a recent case of toxic hepatitis
has been interesting in this report.

The analysis of

the morbid process involves many physiological considerations as before shown.

If signs of hepatic insuffic-

iency are met, the administration of the drug should
be stopped at once and palliative measures resorted to.
These signs appear early enough to be adequate danger
signals if daily vigilance is possible.
Physicians in general practice and in most of the
special practices of medicine and surgery have no
choice about using these drugs.

Some have hesitated

because of the occasional toxic reactions.

Others

have been overly zealous without due regard for them.
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The extreme value of these drugs demands that the
physician use them; the possibility of toxic reactions
demands that he use them intelligently.
The precautionary measures needed in using these
drugs are not difficult.

So much laboratory work may

be found an inconvenience but these drugs are often
life-saving measures and deserve the full attention
of the attending physician.

CONCLTJSIONS
1.

It is not the micro-organism so much as the

manner in which that micro-organism manifests itself
in the morbid process in the body, that is concerned
with in determining the therapeutic effects of sulfonamide compounds.
2.

The toxic effects of sulfonamide compounds

need not be feared if daily vigil is kept during administration.
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